<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05626296</url>
  </required_header>
  <id_info>
    <org_study_id>82102823-01</org_study_id>
    <nct_id>NCT05626296</nct_id>
  </id_info>
  <brief_title>Molecular Network Characteristics of Phlegm-heat Syndrome in Ischemic Stroke Based on Multi-omics Integrated Analysis</brief_title>
  <official_title>Molecular Network Characteristics of Phlegm-heat Syndrome in Ischemic Stroke Based on Multi-omics Integrated Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dongzhimen Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dongzhimen Hospital, Beijing</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The molecular characteristics of ischemic stroke with phlegm-heat syndrome and candidate&#xD;
      biomarkers were identified based on multi-omics data. The main purpose of this study is to&#xD;
      validate the molecular characteristics and biomarkers of phlegm-heat syndrome in ischemic&#xD;
      stroke, and to demonstrate the association of biomarkers with clinical outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a cohort study in patients with ischemic stroke. The demographic characteristics, TCM&#xD;
      syndromes, and other baseline information will be recorded. At the same time, baseline&#xD;
      peripheral blood will be collected. These participants will be followed up to 90 days of&#xD;
      onset, and 90-day modified Rankin scale (mRS) scores will be assessed. The collected blood&#xD;
      samples will be tested by multi-factor detection technology for candidate biomarkers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 14, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Omic biomarkers associated with phelm-heat syndrome in ischemic stroke</measure>
    <time_frame>baseline</time_frame>
    <description>Sensitivity, specificity, and area under the ROC curve of omic biomarkers of Phlegm-heat syndrome in ischemic stroke.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Ischemic Stroke, Acute</condition>
  <arm_group>
    <arm_group_label>Phlegm-heat syndrome in ischemic stroke</arm_group_label>
    <description>Phlegm-heat syndrome: the score of &quot;Phlegm-dampness syndrome&quot; ≥10 with the score of &quot;Internal fire syndrome&quot; ≥10 in Diagnostic Scale for Syndrome Elements of Ischemic Stroke</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-phlegm-heat syndrome in ischemic stroke</arm_group_label>
    <description>Non-phlegm-heat syndrome: the score of &quot;Phlegm-dampness syndrome&quot; &lt;10 with the score of &quot;Internal fire syndrome&quot; &lt;10 in Diagnostic Scale for Syndrome Elements of Ischemic Stroke</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged 50 to 80 years with acute ischemic stroke within 72 hours of onset. Moreover,&#xD;
        these patients fit the diagnosis of phlegm-heat syndrome or non-phlegm-heat syndrome.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute ischemic stroke, were confirmed by magnetic resonance imaging (MRI).&#xD;
&#xD;
          -  Symptom onset within 72 hours.&#xD;
&#xD;
          -  Diagnosis of phlegm-heat syndrome or non-phlegm-heat syndrome.&#xD;
&#xD;
          -  Male or female ≥ 50 years and ≤ 80 years.&#xD;
&#xD;
          -  With written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Planned or already receiving intravenous thrombolysis or endovascular treatment.&#xD;
&#xD;
          -  Acute infectious diseases or acute exacerbations of chronic diseases within one month&#xD;
             before enrollment.&#xD;
&#xD;
          -  Patients with previous stroke.&#xD;
&#xD;
          -  Renal or hepatic insufficiency, tumors, immune diseases, severe underlying diseases.&#xD;
&#xD;
          -  Other conditions that may affect the collection and evaluation of clinical information&#xD;
             (e.g., severe aphasia, mental illness).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xinxing Lai</last_name>
    <phone>8615901111280</phone>
    <email>new-star@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dongzhimen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100700</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinxing Lai, M.D.</last_name>
      <phone>15901111280</phone>
      <email>new-star@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>November 14, 2022</study_first_submitted>
  <study_first_submitted_qc>November 19, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2022</study_first_posted>
  <last_update_submitted>March 24, 2023</last_update_submitted>
  <last_update_submitted_qc>March 24, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dongzhimen Hospital, Beijing</investigator_affiliation>
    <investigator_full_name>Ying Gao</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

